Azitra (NYSEAMERICAN:AZTR – Get Free Report) released its earnings results on Wednesday. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.39, FiscalAI reports.
Azitra Stock Performance
NYSEAMERICAN:AZTR traded down $0.05 during trading hours on Thursday, reaching $0.35. 680,929 shares of the company were exchanged, compared to its average volume of 1,885,007. Azitra has a twelve month low of $0.35 and a twelve month high of $4.33. The stock’s 50-day moving average is $0.66 and its 200-day moving average is $1.25.
Wall Street Analysts Forecast Growth
Separately, Maxim Group lowered their target price on shares of Azitra from $13.32 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, September 24th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, Azitra currently has an average rating of “Buy” and an average target price of $4.00.
About Azitra
Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.
Featured Stories
- Five stocks we like better than Azitra
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Forget Netflix—Paramount Skydance’s $3B Plan Is Turning Heads on Wall Street
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- AMD to $300 Looks Easy—Here’s Why $500 Could Be Next
- Do ETFs Pay Dividends? What You Need to Know
- $5B+ in Buybacks: What DraftKings, AppLovin, and Altria Are Telling You
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.
